The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis

The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis

INTRODUCTION: Although GLP-1 agonists have been shown to reduce cardiovascular events, their effect on the progression of subclinical atherosclerosis is not clear. In this respect, it was planned to evaluate cardiovascular risk markers in obese and diabetic patients receiving exenatide therapy. METH...

Full description

Bibliographic Details
Main Authors: Davut Sakız, Murat Çalapkulu, Muhammed Erkam Sencar, Seyit Murat Bayram, İlknur Ozturk Unsal, Muhammed Kizilgul, Bekir Uçan, Mustafa Özbek, Erman Çakal
Format: Article
Language:English
Published: Van Yuzuncu Yil University, School of Medicine 2022-07-01
Series:Van Tıp Dergisi
Subjects:
exenatide
incretin
atherosclerosis
diabetes mellitus
cardiovascular risk
obesity
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-09815

Internet

https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-09815

Similar Items